GLP1R and diabetic kidney disease: Antioxidative and anti-inflammatory effects were demonstrated in multiple rodent models of DKD, where GLP-1 receptor agonist exposure was associated with suppression of oxidative stress, inflammatory cell infiltration of kidney, and reduced activation of proinflammatory cytokines and profibrotic factors [54,55,56,69].